A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors

A Phase 1/1b First-in-human Trial of BMS-986484 as Monotherapy and Combination Therapy in Participants With Advanced Solid Malignancies

The purpose of this study is to assess the safety and tolerability of BMS-986484 administered alone, in combination with nivolumab in participants with advanced/metastatic solid tumors including non-small cell lung cancer (NSCLC), microsatellite stable (MSS) colorectal carcinoma (CRC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), and squamous cell carcinoma of the head and neck (SCCHN).

Inclusion Criteria:

• Locally advanced unresectable, metastatic, or recurrent malignant tumors including non-small cell lung cancer (NSCLC), pancreatic ductal adenocarcinoma (PDAC), gastric/gastroesophageal junction adenocarcinoma (G/GEJC), microsatellite stable colorectal cancer (MSS CRC), and squamous cell carcinoma of the head and neck (SCCHN).
• Must have measurable disease by response evaluation criteria in solid tumors version 1.1 (RECIST v1.1).
• Must have an Eastern Cooperative Oncology Group Performance Status of 0 or 1.

Exclusion Criteria:

• History of or with active interstitial lung disease or pulmonary fibrosis.
• Active, known, or suspected autoimmune disease.
• Serious uncontrolled medical disorders.
• New onset, non-catheter-associated venous thromboembolism within the past 6 months.
• Other protocol-defined Inclusion/Exclusion criteria apply.